Åsmund Larsen

Åsmund Larsen is a Pharmaceuticals Development Manager at Bayer, where they have coordinated innovative cancer therapies based on alpha particle-emitting conjugates since 2014. With a PhD in Analytical Chemistry from the University of Oslo, Åsmund has extensive experience in structural characterization and pharmaceutical imaging agents. They previously worked as a Senior Research Scientist and Project Coordinator at Bayer, and held various research roles at GE Healthcare, Algeta ASA, and Dyno Chemicals. Åsmund's current research focuses on the promising preclinical applications of Th-227 conjugates in treating multiple cancer indications.